(Health Korea News / Soon-ho Lee) Research results have shown that Daewoong Pharmaceutical’s new SGLT-2 inhibitor diabetes treatment drug ‘Enblo Tablet (ingredient name: inavogliflozin)’ is effective in treating heart failure in diabetic patients. It is noteworthy that a statistically significant disease improvement effect was confirmed.
A joint research team consisting of professors from the Department of Cardiovascular Medicine at Yonsei Severance Hospital and Gachon University Gil Hospital conducted a case study evaluating the effect of ‘Enblo Tablet’ on ‘Cardiac Reverse Remodeling’ in heart failure patients with type 2 diabetes. was recently published in ‘IJHF (International Journal of Heart Failure)’, the official English journal of the Korean Society of Heart Failure.
SGLT-2 inhibitors have been confirmed to be effective in treating heart failure through numerous studies. Accordingly, heart failure treatment guidelines also recommend SGLT-2 inhibitors as first-line heart failure treatment therapy.
However, SGLT-2 inhibitors approved by the US FDA for heart failure treatment include AstraZeneca’s Farxiga (ingredient name: dapagliflozin), Boehringer Ingelheim’s Jardiance (ingredient name: empagliflozin), There are only three products, including Lexicon’s ‘Zinquista (ingredient name: sotagliflozin)’.
Among the SGLT-2 inhibitors approved in Korea, only Farxiga and Jardiance have secured indications for heart failure. ‘Enblo Tablet’ is still only used as a treatment for diabetes. Accordingly, the joint research team conducted a case study to confirm the efficacy of ‘Enblo Tablet’ in heart failure patients with type 2 diabetes.
This study was conducted through a retrospective data analysis method on five patients with type 2 diabetes and heart failure who were prescribed ‘Enblo Tablet’ for more than 30 consecutive days at Gachon University Gil Hospital from January 2023 to January 2024. This is the first study to report the treatment of type 2 diabetes patients with heart failure treated with ‘Enblo Tablet’.
The primary endpoint was the relative change in ‘NT-proBNP’, a representative biomarker for heart failure, and the secondary endpoint was left ventricular ejection fraction, a parameter related to structural changes (remodeling) such as size, shape, and thickness of the heart. Median values of (LVEF), left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index (LVESVI), and left atrial volume index (LAVI) % change.
As a result of the study, the NT-proBNP of patients decreased by 64.5% (352 pg/mL) after treatment with ‘Enblo Tablet’. LVEDVI, LVESVI, and LAVI also decreased by 26.3% (9.6mL/㎡), 17.2% (1.6mL/㎡), and 13.2% (7.4mL/㎡), respectively, and the decreases in these indicators were all statistically significant (p=0.043) ). LVEF increased by 2%, but this was not statistically significant.
The research team said, “Although the data sample size was small with 5 people, ‘Enblo Tablet’ showed promising effects in reducing NT-proBNP,” and added, “Reverse remodeling of the left ventricle and left atrium in heart failure patients with diabetes regardless of LVEF. It has also been confirmed that ) can be induced,” he explained.
“In particular, the change in remodeling index was most dramatic in heart failure patients with reduced left ventricular ejection fraction who switched from empagliflozin to ‘Enblow Tablet,’” he said. “These results are consistent with the results of ‘Enblow Tablet’ in cardiac reverse remodeling for heart failure. “It suggests a positive effect,” he added.
Daewoong Pharmaceutical’s ‘Enblo Tablet’, the 36th domestically produced new drug, is a SGLT-2 inhibitor type diabetes treatment that was successfully commercialized for the first time by a domestic pharmaceutical company as a new drug. It demonstrated equivalent efficacy with only 0.3 mg, which is less than 1/30th of existing treatments of the same class, demonstrating excellent blood sugar-lowering effect and safety.
The next blockbuster domestic diabetes drug based on strengths such as a 1% reduction in glycated hemoglobin compared to placebo, a 70% goal blood sugar achievement rate (HbA1c<7%), improvement in cardiovascular risk factors (weight, blood pressure, lipids), and abundant clinical data for Koreans. is attracting attention.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
